News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
695,777 Results
Type
Article (41386)
Company Profile (420)
Press Release (653971)
Section
Business (208169)
Career Advice (1992)
Deals (35928)
Drug Delivery (87)
Drug Development (83198)
Employer Resources (168)
FDA (16283)
Job Trends (15027)
News (351523)
Policy (32962)
Tag
Academia (2618)
Africa (730)
Alliances (50526)
Alzheimer's disease (1203)
Approvals (16207)
Arizona (186)
Artificial intelligence (92)
Asia (38259)
Australia (6345)
Bankruptcy (360)
Best Places to Work (11545)
Biotechnology (317)
Breast cancer (77)
C2C Services and Suppliers (79621)
California (2204)
Canada (1021)
Cancer (644)
Career advice (1661)
Cell therapy (162)
China (167)
Clinical research (65210)
Collaboration (209)
Colorado (89)
Compensation (113)
Connecticut (93)
COVID-19 (2559)
Cystic fibrosis (82)
Data (483)
Diabetes (101)
Diagnostics (6066)
Drug pricing (80)
Earnings (84919)
Employer resources (143)
Europe (83293)
Events (111509)
Executive appointments (188)
FDA (16591)
Florida (312)
Funding (195)
Gene therapy (118)
Georgia (69)
GLP-1 (559)
Government (4391)
Healthcare (18943)
Hotbed/Location (488248)
Illinois (285)
Indiana (157)
Infectious disease (2600)
Inflammatory bowel disease (99)
Interviews (306)
IPO (16494)
Job creations (3691)
Job search strategy (1424)
Kansas (96)
Layoffs (427)
Legal (7911)
Lung cancer (126)
Manufacturing (114)
Maryland (452)
Massachusetts (1843)
Medical device (13221)
Medtech (13226)
Mergers & acquisitions (19343)
Metabolic disorders (306)
Michigan (132)
Minnesota (233)
Neuroscience (1395)
New Jersey (666)
New York (680)
NextGen Class of 2024 (6707)
Non-profit (4525)
North Carolina (668)
Northern California (937)
Obesity (184)
Ohio (116)
Opinion (189)
Patents (81)
Pennsylvania (637)
People (57294)
Pharmaceutical (81)
Phase I (20387)
Phase II (28769)
Phase III (21335)
Pipeline (142)
Postmarket research (2587)
Preclinical (8726)
Radiopharmaceuticals (246)
Rare diseases (161)
Real estate (5991)
Regulatory (21723)
Research institute (2400)
Resumes & cover letters (349)
South America (1104)
Southern California (877)
Startups (3745)
Texas (286)
United States (9840)
Vaccines (510)
Washington State (280)
Weight loss (152)
Date
Last 7 days (675)
Last 30 days (2623)
Last 365 days (37629)
2024 (28349)
2023 (41013)
2022 (52276)
2021 (56765)
2020 (54924)
2019 (47419)
2018 (35697)
2017 (33026)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27110)
2012 (29220)
2011 (29863)
2010 (27992)
695,777 Results for "tizona therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024
Tizona Therapeutics, Inc. announced first-in-human Phase 1b clinical data of TTX-080, a novel, first-in-class, antibody targeting HLA-G, in patients with metastatic colorectal cancer and locally advanced/metastatic head and neck squamous cell carcinoma.
May 23, 2024
·
5 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Business
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
Gain Therapeutics, Inc. announces that Matthias Alder has departed the Company in order to pursue other opportunities.
June 27, 2024
·
5 min read
Press Releases
ReCerise Therapeutics Inc. Selected for Government Project by MOTIE
Initiates Development of Tailored Innovative Targeted Therapy for Refractory Cancer ReCerise Therapeutics Inc., has announced its selection for a grant from the Ministry of Trade, Industry and Energy of South Korea.
July 1, 2024
·
2 min read
Pharm Country
Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced plans to accelerate its development initiatives in obesity and cardiometabolic disease through the acquisition of the assets of Better Therapeutics, Inc.
May 22, 2024
·
7 min read
Press Releases
Qualigen Therapeutics, Inc. Announces management changes.
September 27, 2024
·
3 min read
Deals
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
Agile Therapeutics, Inc. today announced that it has entered into a definitive merger agreement (“Merger Agreement”) with Insud Pharma, S.L.
June 26, 2024
·
10 min read
Biotech Bay
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announced it successfully executed pre-IND manufacturing activities for its lead therapeutic, CER-1236.
June 13, 2024
·
4 min read
Bio NC
SNP Therapeutics Inc and Fullscript announce Genate test integration to support health professional precision nutrition recommendations in reproductive health
SNP Therapeutics Inc announced today that its Genate Prenatal Nutrition Test can now support healthcare professionals utilizing the Fullscript platform.
June 26, 2024
·
3 min read
Deals
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination
Qualigen Therapeutics, Inc. announced today that on May 23, 2024, it received written notice (the “Delist Notice”) from The Nasdaq Stock Market (“Nasdaq”) indicating the Company’s continued non-compliance with the minimum bid price requirement, pursuant to Listing Rule 5550(b)(2).
May 30, 2024
·
5 min read
1 of 69,578
Next
